A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma

PHASE3RecruitingINTERVENTIONAL
Enrollment

252

Participants

Timeline

Start Date

December 21, 2023

Primary Completion Date

January 31, 2025

Study Completion Date

July 31, 2026

Conditions
Multiple Myeloma
Interventions
DRUG

BCD-264

IV, 16 mg/kg

DRUG

Darzalex

IV, 16 mg/kg

Trial Locations (14)

Unknown

RECRUITING

Chelyabinsk Regional Clinical Hospital, Chelyabinsk

RECRUITING

Kuzbass Regional Clinical Hospital named after S.V. Belyaev, Kemerovo

RECRUITING

Regional Clinical Hospital, Krasnoyarsk

RECRUITING

Moscow City Clinical Hospital 52, Moscow

RECRUITING

S.P. Botkin Moscow City Clinical Hospital, Moscow

RECRUITING

Almazov National Medical Research Centre, Saint Petersburg

RECRUITING

N.N. Petrov National Medicine Research Center of oncology, Saint Petersburg

RECRUITING

Russian Research Institute of Hematology and Transfusiology of the Federal Medical and Biological Agency, Saint Petersburg

RECRUITING

St Petersburg State I.P. Pavlov Medical University, Saint Petersburg

RECRUITING

State budgetary healthcare institution Leningrad Regional Clinical Hospital, Saint Petersburg

RECRUITING

Samara State Medical University, Samara

RECRUITING

Oncological dispensary No. 2 of the Ministry of Health of the Krasnodar Territory, Sochi

RECRUITING

Bashkir State Medical University, Ufa

RECRUITING

Sverdlovsk Regional Clinical Hospital No. 1, Yekaterinburg

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biocad

INDUSTRY